Epidemiology and antimicrobial resistance rates for Shigella species in a resource-rich setting

Samuel Baumgart; Thuy Phan; Genevieve McKew

doi:10.1016/j.pathol.2024.07.004

Epidemiology and antimicrobial resistance rates for Shigella species in a resource-rich setting

Pathology. 2025 Feb;57(1):94-99. doi: 10.1016/j.pathol.2024.07.004. Epub 2024 Sep 25.

Authors

Samuel Baumgart¹, Thuy Phan², Genevieve McKew³

Affiliations

¹ Department of Microbiology and Infectious Diseases, Concord Repatriation General Hospital, NSW Health, Concord, NSW, Australia.
² Department of Microbiology and Infectious Diseases, Concord Microbiology, NSW Health Pathology, Concord, NSW, Australia.
³ Department of Microbiology and Infectious Diseases, Concord Repatriation General Hospital, NSW Health, Concord, NSW, Australia; Department of Microbiology and Infectious Diseases, Concord Microbiology, NSW Health Pathology, Concord, NSW, Australia; Concord Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Sydney Infectious Diseases Institute, University of Sydney, Sydney, NSW, Australia. Electronic address: genevieve.mckew@sydney.edu.au.

PMID: 39455321
DOI: 10.1016/j.pathol.2024.07.004

Abstract

Shigellosis is an acute, often dysenteric, diarrhoeal illness that is responsible for much morbidity and mortality worldwide. Increasing rates of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Shigella species have been detected worldwide and a regular review of local epidemiological and resistance rates is necessary to help guide empirical antibiotic choice. This retrospective laboratory study of faecal isolates between 2013 and 2023 demonstrates increasing rates of resistance to third-generation cephalosporins, azithromycin and ciprofloxacin, alongside an overall increase in MDR and XDR isolates.

Keywords: EIEC; Shigella; antimicrobial resistance; enteroinvasive Escherichiacoli; shigellosis.

MeSH terms

Adolescent
Adult
Anti-Bacterial Agents* / pharmacology
Anti-Bacterial Agents* / therapeutic use
Azithromycin / pharmacology
Azithromycin / therapeutic use
Child
Child, Preschool
Drug Resistance, Bacterial
Drug Resistance, Multiple, Bacterial
Dysentery, Bacillary* / drug therapy
Dysentery, Bacillary* / epidemiology
Dysentery, Bacillary* / microbiology
Feces / microbiology
Female
Humans
Infant
Male
Microbial Sensitivity Tests
Middle Aged
Retrospective Studies
Shigella* / drug effects
Shigella* / isolation & purification

Substances

Anti-Bacterial Agents
Azithromycin